实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
2期
217-219,224
,共4页
陈菊香%周红轩%朱利群%潘琴
陳菊香%週紅軒%硃利群%潘琴
진국향%주홍헌%주리군%반금
奥沙利铂%替吉奥%吉西他滨%晚期胆道癌
奧沙利鉑%替吉奧%吉西他濱%晚期膽道癌
오사리박%체길오%길서타빈%만기담도암
Oxaliplatin%S-1%Gemcitabine%Advanced biliary tract cancer
目的：观察奥沙利铂联合替吉奥治疗晚期胆道癌的临床疗效和不良反应。方法选择经组织病理学确诊的晚期胆道癌患者50例，分为观察组和对照组。观察组采用奥沙利铂130 mg／m2，静脉滴注2 h，第1天；替吉奥胶囊80～120 mg／d，每天2次，第1～14天；每21天为1个周期。对照组采用奥沙利铂130 mg／m2，静脉滴注2 h，第1天；吉西他滨1000 mg／m2，静脉滴注30 min，第1、8天；每21天为1个周期。比较2组的临床疗效和不良反应。结果观察组27例患者中CR 0例，PR 6例，SD 9例，PD 12例；RR 22．2％，DCR 55．6％，中位PFS 4．9个月，中位OS 9．7个月。对照组23例中CR 0例，PR 5例，SD 8例，PD 10例；RR 21．7％，DCR 56．5％，中位PFS 4．5个月，中位OS 9．5个月。2组相比，临床效果差异无统计学意义（P＞0．05）。主要不良反应为白细胞下降、血小板下降、恶心呕吐、肝功能损害、外周神经毒性和皮疹等，多为Ⅰ～Ⅱ度。观察组的血液学毒性和恶心、呕吐发生率低于对照组，差异有统计学意义（P＜0．05）。结论奥沙利铂联合替吉奥治疗晚期胆道癌临床疗效可靠，且不良反应较轻，值得深入研究。
目的：觀察奧沙利鉑聯閤替吉奧治療晚期膽道癌的臨床療效和不良反應。方法選擇經組織病理學確診的晚期膽道癌患者50例，分為觀察組和對照組。觀察組採用奧沙利鉑130 mg／m2，靜脈滴註2 h，第1天；替吉奧膠囊80～120 mg／d，每天2次，第1～14天；每21天為1箇週期。對照組採用奧沙利鉑130 mg／m2，靜脈滴註2 h，第1天；吉西他濱1000 mg／m2，靜脈滴註30 min，第1、8天；每21天為1箇週期。比較2組的臨床療效和不良反應。結果觀察組27例患者中CR 0例，PR 6例，SD 9例，PD 12例；RR 22．2％，DCR 55．6％，中位PFS 4．9箇月，中位OS 9．7箇月。對照組23例中CR 0例，PR 5例，SD 8例，PD 10例；RR 21．7％，DCR 56．5％，中位PFS 4．5箇月，中位OS 9．5箇月。2組相比，臨床效果差異無統計學意義（P＞0．05）。主要不良反應為白細胞下降、血小闆下降、噁心嘔吐、肝功能損害、外週神經毒性和皮疹等，多為Ⅰ～Ⅱ度。觀察組的血液學毒性和噁心、嘔吐髮生率低于對照組，差異有統計學意義（P＜0．05）。結論奧沙利鉑聯閤替吉奧治療晚期膽道癌臨床療效可靠，且不良反應較輕，值得深入研究。
목적：관찰오사리박연합체길오치료만기담도암적림상료효화불량반응。방법선택경조직병이학학진적만기담도암환자50례，분위관찰조화대조조。관찰조채용오사리박130 mg／m2，정맥적주2 h，제1천；체길오효낭80～120 mg／d，매천2차，제1～14천；매21천위1개주기。대조조채용오사리박130 mg／m2，정맥적주2 h，제1천；길서타빈1000 mg／m2，정맥적주30 min，제1、8천；매21천위1개주기。비교2조적림상료효화불량반응。결과관찰조27례환자중CR 0례，PR 6례，SD 9례，PD 12례；RR 22．2％，DCR 55．6％，중위PFS 4．9개월，중위OS 9．7개월。대조조23례중CR 0례，PR 5례，SD 8례，PD 10례；RR 21．7％，DCR 56．5％，중위PFS 4．5개월，중위OS 9．5개월。2조상비，림상효과차이무통계학의의（P＞0．05）。주요불량반응위백세포하강、혈소판하강、악심구토、간공능손해、외주신경독성화피진등，다위Ⅰ～Ⅱ도。관찰조적혈액학독성화악심、구토발생솔저우대조조，차이유통계학의의（P＜0．05）。결론오사리박연합체길오치료만기담도암림상료효가고，차불량반응교경，치득심입연구。
Objective To evaluate the efficacy and adverse reactions of oxaliplatin plus S-1 in the treatment of advanced biliary tract cancer.Methods 50 patients histologically confimed to be advanced biliary tract cancer were divided into the obser-vation group and the control group.The observation group was treated with oxaliplatin 130 mg/m2 for 2 h on the first day,and S-1 capsules 80~120 mg/d,twice a day on days 1~14,every 21 days was 1 cycle.The control group was treated with oxaliplatin 130 mg/m2 for 2 h on the first day,and gemcitabine 1 000 mg/m2 for a 30 minute infusion on day 1,8,every 21 days was 1 cycle. And clinical efficacy and adverse reactions of the 2 groups were compared.Results Among the 27 patients in the observation group,there was 0 CR,6 PR,9 SD,12 PD,the effective rate was 22.2%,disease control rate was 55.6%.And the median PFS and median OS were 4.9 months and 9.7 months,respectively.Among the 23 patients in the control group,there was 0 CR,5 PR, 8 SD,10 PD.the effective rate was 21.7%,the disease control rate was 56.5%.And the median PFS and median OS were 4.5 months and 9.5 months,respectively.There was no statistically significant difference between the 2 groups(P>0.05).The main adverse reactions were leukopenia,thrombocytopenia,nausea,vomiting,liver damage,peripheral neurotoxicity and rash,mostly Ⅰ~Ⅱdegrees.The incidence of hematology toxicity,nausea and vomiting in the observation group was lower than that of the con-trol group,the difference was statistically significant(P<0.05).Conclusion Oxaliplatin plus S-1 in the treatment of advanced biliary tract cancer is effective,and the adverse reactions is lighter,it is worthy of further study.
